Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Deloitte
Harvard Business School
Express Scripts
Chubb
Julphar
QuintilesIMS
Cerilliant

Generated: July 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022156

« Back to Dashboard

NDA 022156 describes CLEVIPREX, which is a drug marketed by Chiesi Usa Inc and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug. Additional details are available on the CLEVIPREX profile page.

The generic ingredient in CLEVIPREX is clevidipine. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the clevidipine profile page.
Summary for 022156
Tradename:CLEVIPREX
Applicant:Chiesi Usa Inc
Ingredient:clevidipine
Patents:2
Generic Entry Opportunity Date for 022156
Generic Entry Date for 022156*:
Constraining patent/regulatory exclusivity:
Dosage::
EMULSION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022156
Ingredient-typeDihydropyridines
Mechanism of ActionCalcium Channel Antagonists
Suppliers and Packaging for NDA: 022156
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156 NDA Chiesi USA, Inc. 10122-610 N 10122-610-10
CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156 NDA Chiesi USA, Inc. 10122-611 N 10122-611-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:EMULSION;INTRAVENOUSStrength25MG/50ML (0.5MG/ML)
Approval Date:Aug 1, 2008TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 5, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
Patent:➤ Try a Free TrialPatent Expiration:Oct 10, 2031Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:EMULSION;INTRAVENOUSStrength50MG/100ML (0.5MG/ML)
Approval Date:Aug 1, 2008TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 5, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

Expired US Patents for NDA 022156

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Harvard Business School
Fuji
Farmers Insurance
McKinsey
Fish and Richardson
AstraZeneca
Cipla
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.